NYSE:ABT
Abbott Laboratories Stock News
$104.87
+0.280 (+0.268%)
At Close: May 16, 2024
Abbott rumored to endorse Trump during border visit
03:45am, Friday, 17'th Nov 2023
Rep. Carlos Gimenez, R-Fla., discusses former President Donald Trump's upcoming trip to Texas on 'The Evening Edit.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
10:34am, Wednesday, 15'th Nov 2023
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
11:13am, Friday, 10'th Nov 2023
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
15 stocks with the closest US government connections
09:32am, Thursday, 09'th Nov 2023
Quiver Quantitative, the pioneering company behind an alternative data platform designed for retail investors, has been actively tracking stock market trades made by US Congress members and other poli
Abbott India's Q2 profit climbs on strong sales
03:44am, Thursday, 09'th Nov 2023
Abbott India , the local unit of U.S. healthcare firm Abbott Laboratories , reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment.
2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity
09:37am, Wednesday, 08'th Nov 2023
The rise of weight-loss treatments has some investors worried about demand for certain medical devices. Yet, DexCom and Abbott Labs still see strong sales for their continuous glucose monitoring devic
3 Dividend Kings to Buy for Royal Returns
03:48pm, Monday, 06'th Nov 2023
Investing in the stock market is a journey of both patience and foresight. Dividend kings reign supreme in this realm, offering high-yield dividends and long-term investment opportunities.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
10:33am, Friday, 03'rd Nov 2023
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
1 Stock Down 15% This Year to Buy and Hold Forever
10:15am, Thursday, 02'nd Nov 2023
Abbott Labs' sales have fluctuated in recent years, but its underlying business is solid. Its most important unit should continue performing well despite competitive pressures.
Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
09:57am, Wednesday, 01'st Nov 2023
Thermo Fisher and Abbott are two of our key Healthcare holdings in our fund, and both are among our top 10 holdings overall. Abbott and Thermo Fisher focus on different industries which are Healthcare
FDA issues warning letter to Abbott for probiotic products for infants
11:24am, Thursday, 26'th Oct 2023
The U.S. Food and Drug Administration said on Thursday it has issued a warning letter to Abbott Laboratories for the company's probiotic products sold under the brand Similac Probiotic Tri-Blend for u
ZBH or ABT: Which Is the Better Value Stock Right Now?
12:47pm, Wednesday, 25'th Oct 2023
Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). But which of these two companies is the best option for those looking f
5 Stocks to Watch on Solid Revenues in Last Reported Quarter
09:48am, Wednesday, 25'th Oct 2023
We have narrowed our search to five U.S. corporate behemoths. These are: JPM, UNH, PG, ABT, FCX.
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
06:30am, Wednesday, 25'th Oct 2023
If you look at MarketBeat's list of dividend aristocrats, you'll see a select group of publicly traded companies that have an outstanding track record of consistently increasing their dividend payouts
Abbott Laboratories May Soon Launch a Game-Changing New Device in the U.S.
10:01am, Tuesday, 24'th Oct 2023
Abbott Laboratories' business has underwhelmed investors in 2023, as testing numbers are down big. Growth in its medical devices was the only bright spot in the company's recent earnings report.